Literature DB >> 12437407

Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections.

Ebbing Lautenbach1, Neil O Fishman, Warren B Bilker, Analia Castiglioni, Joshua P Metlay, Paul H Edelstein, Brian L Strom.   

Abstract

BACKGROUND: The incidence of fluoroquinolone (FQ) resistance has increased markedly in recent years. Even in the common nosocomial pathogens Escherichia coli and Klebsiella pneumoniae, in which the emergence of FQ resistance was believed to be unlikely, increasing resistance to these agents has been noted. Risk factors for FQ resistance in these pathogens remain unknown. Although FQs are important components of the present antimicrobial arsenal, their continued usefulness is threatened by rising FQ resistance.
OBJECTIVE: To identify risk factors for nosocomial FQ resistance.
METHODS: A case-control study of hospitalized patients with infections due to FQ-resistant and FQ-susceptible E coli and K pneumoniae occurring between January 1, 1998, and June 30, 1999.
RESULTS: We included 123 patients with nosocomial FQ-resistant infections and 70 randomly selected patients with nosocomial FQ-susceptible infections. Independent risk factors (adjusted odds ratio [95% confidence interval]) for FQ resistance were (1) recent FQ use (5.25 [1.81-15.26]); (2) residence in a long-term care facility (3.65 [1.64-8.15]); (3) recent aminoglycoside use (8.86 [1.71-45.99]); and (4) older age (1.03 [1.01-1.06]).
CONCLUSIONS: Recent FQ use, residence in a long-term care facility, recent aminoglycoside use, and older age were all noted to be independent risk factors for FQ resistance among patients with nosocomial E coli and K pneumoniae infections. Efforts should be directed at recognition and modification of these risk factors to curb the rise in FQ resistance and preserve the utility of these agents in the treatment of common nosocomial gram-negative infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12437407     DOI: 10.1001/archinte.162.21.2469

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  27 in total

1.  The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia.

Authors:  Bernard C Camins; Jonas Marschall; Shannon R DeVader; Dawn E Maker; Matthew W Hoffman; Victoria J Fraser
Journal:  J Hosp Med       Date:  2011 Jul-Aug       Impact factor: 2.960

2.  Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.

Authors:  P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal:  J Hosp Infect       Date:  2010-12       Impact factor: 3.926

Review 3.  Antimicrobial resistance in hospitals: how concerned should we be?

Authors:  Michael R Mulvey; Andrew E Simor
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

Review 4.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

5.  Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.

Authors:  Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2013-08-23       Impact factor: 3.254

6.  Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.

Authors:  Robert E Fintelmann; Eliza N Hoskins; Thomas M Lietman; Jeremy D Keenan; Bruce D Gaynor; Vicky Cevallos; Nisha R Acharya
Journal:  Arch Ophthalmol       Date:  2011-04

7.  Colonization with extraintestinal pathogenic Escherichia coli among nursing home residents and its relationship to fluoroquinolone resistance.

Authors:  Joel N Maslow; Ebbing Lautenbach; Thomas Glaze; Warren Bilker; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance.

Authors:  Cheol-In Kang; Sung-Han Kim; Ji-Whan Bang; Hong-Bin Kim; Nam-Joong Kim; Eui-Chong Kim; Myoung-don Oh; Kang-Won Choe
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

9.  Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Mark G Weiner; Warren B Bilker; Pam Tolomeo; Xiangqun Mao; Irving Nachamkin; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-01       Impact factor: 3.254

10.  SHEA/APIC guideline: infection prevention and control in the long-term care facility, July 2008.

Authors:  Philip W Smith; Gail Bennett; Suzanne Bradley; Paul Drinka; Ebbing Lautenbach; James Marx; Lona Mody; Lindsay Nicolle; Kurt Stevenson
Journal:  Infect Control Hosp Epidemiol       Date:  2008-09       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.